156170-24-0

Upstream product

• 126-81-8 dimedone 
• 6267-39-6 3-ethoxy-5,5-dimethyl-2-cyclohexen-1-one 
• 74-88-4 methyl iodide 

Downstream Products

• 73228-88-3 4,5,5-trimethylcyclohex-2-en-1-one 
• 850254-57-8 5-[2-(3-isopropyl-4,5-dimethoxy-phenyl)-2-methoxycarbonyloxy-ethyl]-4,4,5-trimethyl-2-oxo-cyclohexanecarboxylic acid methyl ester 
• 850254-52-3 3-[2-(3-isopropyl-4,5-dimethoxy-phenyl)-2-methoxycarbonyloxy-ethyl]-3,4,4-trimethyl-6-oxo-cyclohex-1-enecarboxylic acid methyl ester 
• 850254-59-0 3-[(E)-2-(3-Isopropyl-4,5-dimethoxy-phenyl)-vinyl]-3,4,4-trimethyl-6-oxo-cyclohex-1-enecarboxylic acid methyl ester 
• 850254-56-7 4-[2-hydroxy-2-(3-isopropyl-4,5-dimethoxy-phenyl)-ethyl]-3,3,4-trimethyl-cyclohexanone 
• 850254-61-4 4-[(E)-2-(3-Isopropyl-4,5-dimethoxy-phenyl)-vinyl]-3,3,4-trimethyl-cyclohexanone 
• 850254-55-6 4-(2-hydroxy-ethyl)-3,3,4-trimethyl-cyclohexanone 
• 850254-50-1 (1,2,2-trimethyl-4-oxo-cyclohexyl)-acetaldehyde 
• 850254-53-4 (4-ethoxy-1,6,6-trimethyl-2-oxo-cyclohex-3-enyl)-acetic acid ethyl ester 

Relevant academic research and scientific papers

The total synthesis of pygmaeocin C

Making use of a recently developed intramolecular Friedel-Crafts alkylation process as the key operation, the first total synthesis, in racemic form, of pygmaeocin C has been achieved. Georg Thieme Verlag Stuttgart.

Non-steroid progesterone receptor agonist and antagonist and compounds and methods

Non-steroidal compounds which are high affinity, high specificity ligands for progesterone receptors are disclosed. The compounds include synthetic derivatives of cyclocymopol and its diastereomers, spectroscopically and chromatographically pure (3R)-cyclocymopol monomethyl ether, which functions as a progesterone receptor antagonist, and spectroscopically and chromatographically pure (3S)-cyclocymopol monomethyl ether, which functions as a progesterone receptor agonist. Also disclosed are methods for employing the disclosed compounds for modulating processes mediated by progesterone receptors and for treating patients requiring progesterone receptor agonist or antagonist therapy.